Table 1 Patients characteristics at baseline (n = 382)
Present study n = 382 | Strategy–PI Arribas et al. [10] n = 293 | Strategy– NNRTI Pozniak et al. [9] n = 291 | |
|---|---|---|---|
Male gender | 267 (69.9) | 250 (85.0) | 268 (92.0) |
Age (Years) | 44 [38 − 5] | 41 [33–48] | 43[34–49] |
Region of origin | NA | NA | |
Europe | 181 (48.0) | ||
Sub–Saharan Africa | 135 (35.8) | ||
North Africa | 22 (5.8) | ||
Other | 39 (10.3) | ||
Mode of HIV infection | NA | NA | |
Heterosexual | 189 (49.5) | ||
MSM | 151 (39.5) | ||
Intravenous drug users, transfusion, others | 42 (11.0) | ||
Time since HIV infection diagnosis (years) | 11 [5–16] | 4 [3–7] | 5 [3–7] |
History of ART change because of virologic failure | 95 (24.6) | 0 | 0 |
Nadir CD4 cell count (cell/mm3) | 232 [108–353] | ||
CD4 cell count at baseline (cell/mm3) | 614 [450.7–812.7] | 564 [423–757] | 561 [450–722] |
Creatinine levels at baseline (µmoL/L) | 79 [70–89] | ||
eGFR (mL/min) | NA | 111.2 [96.0–127.9) | 114.4 [99.7–132.4] |
Time between first ART and switch to E/C/F/TDF (years) | 7 [4–13] | 3 [2–4] | 4 [2–5] |
Duration of HIV RNA < 50 copies/mL before the switch, months | 32 [11–62] | ||
On first or second ART regimen before the switch | 95 (25.0) | 293 (100.0) | 291 (100.0) |
ART before the switch | |||
2NRTI + 1PI/r§ | 195 (51.0) | 293 (100.0) | 0 |
2NRTI + 1NNRTI§§ | 84 (22.0) | 0 | 291 (100.0) |
2 NRTI + 1INSTI§§§ | 67 (17.5) | 0 | 0 |
Other PI/r–based regimens | 16 (4.2) | 0 | 0 |
Other combinations | 20 (5.2) | 0 | 0 |
Reason for the switch | NA | NA | |
Simplification | 256 (67.0) | ||
Tolerance | 85 (22.3) | ||
Patients demand | 4 (1.1) | ||
Other or unknown* | 37 (9.7) |